Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia
A Randomized, Open-label, Single and Multiple-dose, Parallel-design Phase 1/2a Clinical Trial to Evaluate the Pharmacokinetics/Pharmacodynamics and Safety of AD-303A and Oral Administration of AD-3031 in Male Androgenetic Alopecia Patients
In the register
The register attaches this trial to AD-303 (topical dutasteride) (Moogene Medi), currently at “Phase 1/2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Not yet recruiting
- Declared phase
- Phase 1/2
- Sponsor
- Moogene Medi Co., Ltd
- Participants (registry)
- 30
- Start
- April 2026 (planned)
- Primary completion
- September 2026
- Study completion
- December 2026 (planned)
- Last registry update
- March 2026
- Countries
- South Korea
Conditions studied: Androgenetic Alopecia
Interventions: AD-303A, AD-3031
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.